Stoke Therapeutics, Inc. (STOK) Form 10-Q — Nov 3, 2026
Stoke Therapeutics reported a Q3 2026 net loss of $73.6 million, nearly double the $38.3 million loss a year earlier, as operating expenses surged on Phase 3 zorevunersen buildout. Nine-month net loss reached $185.3 million versus net income of $51.0 million in the prior-year period, which had benefited from $162.3 million of Biogen collaboration revenue that has largely been recognized. The company ended the quarter with $358.8 million in cash, cash equivalents and marketable securities, which it says funds operations into early 2028.
Key figures
- Revenue
- 11255000
- Revenue Yoy
- +5.9% vs $10.6M in Q3 2025
- Cash Position
- 358800000
- R and d expense q3
- 59831000
- Shares outstanding
- 65406268
- Accumulated deficit
- 683000000
- Sg and a expense q3
- 28739000
- Atm net proceeds to date
- 146400000
- Nine month net income 2025
- 51049000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.